LivaNova Tops Q3 Revenue Estimates and Lifts Full-Year 2026 Guidance
LIVN sits 64% above its 52-week low of $48.82.
Summary
LivaNova posted Q3 revenue of $393.1M (+9.9%) and adjusted diluted EPS of $1.23, then raised full-year 2026 revenue growth guidance to 9%-10% and adjusted EPS to $4.40-$4.50.
Key Events · Earnings and Guidance · LIVN
-
Q3 Revenue Grows 9.9% to $393.1M
Cardiopulmonary revenue rose 10.9% to $225.3M and Neuromodulation 11.1% to $166.1M, with growth across all regions.
-
Full-Year Guidance Raised on Both Lines
Constant-currency revenue growth guidance lifted to 9%-10% from 8%-9%, and adjusted diluted EPS to $4.40-$4.50 from $4.30-$4.40, a $0.10 midpoint increase.
-
GAAP EPS Falls on Litigation and Derivative Items
GAAP diluted EPS was $0.11 versus $0.49 a year ago, reflecting $34.0M of other operating expense and a $28.2M fair-value gain on the 2029 Notes conversion option deducted from the diluted numerator; adjusted diluted EPS rose to $1.23 from $1.11.
-
Cash Generation Holds at $55.8M Adjusted FCF
Q3 operating cash flow was $73.7M and adjusted free cash flow $55.8M; the full-year adjusted free cash flow range of $140M-$160M was maintained.
Analysis · LIVN · Industrial Applications And Services
The guidance raise is the headline here, not the top-line beat. LivaNova grew Q3 revenue 9.9% to $393.1M and lifted full-year 2026 guidance on both lines: constant-currency revenue growth to 9%-10% from 8%-9%, and adjusted diluted EPS to $4.40-$4.50 from $4.30-$4.40. Adjusted EPS of $1.23 rose from $1.11 a year ago, while GAAP diluted EPS fell to $0.11 from $0.49. That decline reflects a $28.2M gain on the 2029 Notes conversion option change in fair value deducted from the diluted numerator, plus $34.0M of other operating expense tied largely to the 3T Heater-Cooler litigation provision. By resetting the earnings base for the year, the raise carries more weight than the quarter itself, and it comes with a maintained $140M-$160M adjusted free cash flow range.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LIVN was trading at $79.90 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $4.4B. The 52-week trading range was $48.82 to $85.76. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.